Schwarz Pharma Acquires Rights to Drug for Epilepsy

February 2000
Worldwide Biotech;Feb2000, Vol. 12 Issue 2, p8
Trade Publication
Focuses on the rights acquired by Schwarz Pharma to complete the development and commercialization of Harkoseride, a novel drug in the area of central nervous system disease.


Related Articles

  • COMPANY SPOTLIGHT -- Schwarz Pharma.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p19 

    The article features Schwarz Pharma, a company engaged in research and development, production, marketing, and distribution of pharmaceutical products. It has a drug development team engaged in developing drugs for the treatment of neurological and urological disorders. The company's products...

  • Schwarz: lacosamide on track for dual approval.  // PharmaWatch: CNS;January 2005, Vol. 4 Issue 1, p4 

    Comments on the results of Schwarz Pharma AG's phase IIb lacosamide trial. Efficacy of oral lacosamide as an epileptic drug; Schedule on the global launch of the drug; Growth in the anticonvulsant market.

  • Moexipril gets June launch.  // Drug Topics;5/22/95, Vol. 139 Issue 10, p8 

    Reports on Schwarz Pharma's launching of Univasc or moexipril in June 1995. Drug as the tenth ACE inhibitor to enter the United States market.

  • Schwarz paying for switches.  // Drug Topics;1/24/94, Vol. 138 Issue 2, p6 

    Reports on Schwarz Pharma's offer of five dollars to pharmacists who convince patients and their doctors to switch a prescription for isosorbide mononitrate, Wyeth-Ayerst, Laboratories (Ismo), to Schwarz's generic version of the drug, Monoket.

  • Generic firm offers incentive for switch hitters. Muirhead, Greg // Drug Topics;2/7/94, Vol. 138 Issue 3, p94 

    Reports on generic drugs manufacturer Schwarz Pharma's payment of pharmacists who convince patients and their doctors to switch a prescription to the company's drug. Advantages of the program; Contact information.

  • Income to soar for Schwarz.  // European Chemical News;2/24/2003, Vol. 78 Issue 2041, p9 

    Presents a forecast on the net income of Schwarz Pharma in 2003. Sales outlook; Factors that would influence the income of Schwarz.

  • Schwarz Pharma stays positive.  // Life Science Today;Dec2000, Vol. 1 Issue 6, p6 

    Reports on the decline of the profits earned by Schwarz Pharma in Germany.

  • New packaging.  // Drug Topics;4/19/99, Vol. 143 Issue 8, p115 

    Informs about the latest packaging of Schwarz Pharma Inc.'s Colyte, an oral solution for cleansing the bowel before colonoscopy or barium enema X-ray examination.

  • DTC coming for Verelan? Dickinson, James G. // Medical Marketing & Media;May99, Vol. 34 Issue 5, p36 

    Reports on Schwarz Pharma's consideration of launching a direct-to-consumer campaign as part of the product launch of Verelan PM (verapamil hydrochloride), a calcium channel blocker.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics